Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on treating cancer with Veyonda®, its lead drug candidate.

Veyonda® is a dual-acting oncotoxic and immuno-oncology drug designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapy, radiotherapy and immuno-oncology drugs. The drug acts by harnessing the body’s immune system to inflict damage oncancer cells in the body and has shown promise in treating a broad spectrum of cancers.

Noxopharm also has an active research and development (R&D) program for additional drug candidates and is the major shareholder of US biotechnology company Nyrada Inc. (ASX:NYR).

Media Releases

Noxopharm - Independent Discovery Validates DARRT Cancer Therapy (ASX:NOX)

Nov 2020 11:17 AM

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to note that a recent discovery by a major U.S. university group significantly validates the Company’s...read more
Noxopharm - Veyonda To Be Tested In Combination With Opdivo In Trial (ASX:NOX)

Nov 2020 10:44 AM

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce that NOX have joined with Principal Investigator, Professor Paul De Souza, and three Sydney hosp...read more
Noxopharm Announces Dedicated Septic Shock Company Established (ASX:NOX)

Nov 2020 12:03 PM

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce a partnership with Hudson Institute of Medical Research (‘Hudson Institute’) and a c...read more
Noxopharm - First COVID-19 Patient Treated in Veyonda Study (ASX:NOX)

Oct 2020 08:57 AM

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce the enrolment and treatment of the first patient into the Phase 1 NOXCOVID-1 study examini...read more
Noxopharm Announces Veyonda COVID-19 Study Approved For Immediate Start (ASX:NOX)

Sep 2020 09:11 AM

Australian drug development companyNoxopharm Limited (ASX: NOX) today announces the commencement of a clinical study of Veyonda® in COVID-19 patients. Following review by expert panels, official...read more
Noxopharm Announces Peer-Reviewed Publication Strengthens Case for Veyonda (ASX:NOX)

Aug 2020 09:46 AM

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce the publication of the first manuscript of the LuPIN trial in the journal, European Urology Onco...read more
Noxopharm Announces Data Shows Idronoxil Holds Key to Problem of COLD Cancers (ASX:NOX)

Jul 2020 09:32 AM

Important pre-clinical data from two independent research groups confirms that idronoxil (IDX), the active ingredient in Veyonda, achieves a major goal in restoring cancer-fighting immune function w...read more
Noxopharm Announces COVID-19 Trial Program to Commence in Europe (ASX:NOX)

Jun 2020 09:50 AM

NOX announces commencement of its NOXCOVID clinical program with a planned Phase 1 trial in Europe. This action is designed to provide important safety data and proof-of-principle of Veyonda as a po...read more
Noxopharm Announces ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer (ASX:NOX)

Jun 2020 10:45 AM

Noxopharm (ASX: NOX) today reports on the public release at a global oncology conference of 2 sets of clinical data relating to the development of NOX66 (Veyonda®) as a treatment of end-stage ca...read more
Noxopharm announces FDA allows Veyonda Pre-IND Submission for COVID-19 (ASX:NOX)

May 2020 07:30 AM

Noxopharm (ASX:NOX) today announces that on advice from the U.S. Food and Drug Administration (FDA), the Company has lodged a pre-Investigational New Drug (pre-IND) submission for a clinical trial o...read more

Viewing: 11 - 20 of 169 < Previous | Next >

Latest Company News

Videos

Oct 2020 01:05 PM

Noxopharm (ASX:NOX) announces ..

09 Oct 2020 - Noxopharm Limited (ASX:NOX) Chief Medical Officer Dr Gisela Mautner provides an update on the company's lead drug candidate Veyonda in its DARRT program and discusses a new trial program for COVID-19.

Noxopharm (ASX:NOX) - Converti...

Jul 23 2020 - 23 Jul 2020 - Noxopharm Limited (ASX:NOX) Executive Chairman and CEO Dr Graham Kelly discusses important pre-clinical results for the co...